León-Cachón Rafael Baltazar Reyes, Ascacio-Martínez Jorge Ángel Isidro, Gómez-Silva Magdalena, Piñeyro-Garza Everardo, González-González José Gerardo, Pogue Gregory, Simón-Buela Laureano, Barrera-Saldaña Hugo Alberto
Basic Science Department, Health Science Division, Universidad de Monterrey, San Pedro Garza García, N.L., México.
Biochemical and Molecular Medicine Department, Faculty of Medicine, Universidad Autónoma de Nuevo León, Monterrey, N.L., México.
Rev Invest Clin. 2015 Jul-Aug;67(4):212-8.
Technology is the basis of scientific progress and is an essential component for continued competitiveness in industry. The development of a new drug candidate is a long and expensive process, in which a molecule undergoes several stages of research (both pre-clinical and clinical) before being approved for commercialization. Scientific progress has revolutionized the pharmaceutical industry and reshaped the processes by which new drugs are discovered, investigated, and developed. Currently, the influence of genomic variations in drug metabolism must be better understood to predict an individual´s response to a given treatment. Employing genomics tools, an individual's genetic profile may be obtained and used as the basis for prescription of the best treatment option, thus personalizing medicine. In this review, we discuss how current mainstream genomic technologies used in clinical pharmacology research can accelerate the identification of populations that can benefit the most while reducing adverse events.
技术是科学进步的基础，也是工业持续竞争力的重要组成部分。新药候选物的开发是一个漫长且昂贵的过程，在此过程中，一个分子要经历几个研究阶段（临床前和临床阶段），才能获得商业化批准。科学进步彻底改变了制药行业，重塑了新药发现、研究和开发的流程。目前，必须更好地理解药物代谢中基因组变异的影响，以预测个体对特定治疗的反应。利用基因组学工具，可以获取个体的基因图谱，并将其作为开具最佳治疗方案处方的依据，从而实现个性化医疗。在本综述中，我们讨论了临床药理学研究中使用的当前主流基因组技术如何能够加速识别最能受益的人群，同时减少不良事件。
